MS patients had significantly higher detectable levels of released IFN-γ (median SARS-CoV-2 IFN-γ 3572 mIU/mL vs. controls 1545 mIU/mL, p < 0.0014). The gene discussed is IFNG; the disease is myeloid sarcoma.